Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha.
Verma
Dushyant
D
Kantarjian
Hagop
H
Jain
Nitin
N
Cortes
Jorge
J
D000368:Aged; D001549:Benzamides; D020732:Cytogenetic Analysis; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods
D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate